Full index of posts »
StockTalks
-
Simon Property Group, Inc. ( $SPG ) Earns $1 Billion Free Cash Flow from Operations After Dividend and Capex - http://su.pr/556kgt about 14 hours ago
-
Two Harbors Investment Corp. ( $TWO ) Exposed to Nonagency RMBS; Hybrid REITs Tied to Macro Improvement - http://su.pr/2BAOol about 16 hours ago
-
Starwood Property Trust ( $STWD ) Expected to Ramp Earnings and Dividends After LNR Acquisition - http://su.pr/2Y7UaD about 16 hours ago
Posts by Themes
Animal Health,
animal health,
Banks,
Business Development Companies,
China,
Commodities,
Consumer,
consumer goods,
Consumer Goods,
consumer products,
Dividend Investing,
dividend-ideas,
dividends,
Financial,
financials,
Gold,
gold and precious metals,
Guns,
high-yield stocks,
Income Investing Strategies,
income investing strategy,
income-investing-strategy,
India,
Industrial,
large cap pharmaceuticals,
Long Short Ideas,
long-ideas,
Master Limited Partnerships,
Mining Companies,
oil and gas MLPs,
Oil and Gas MLPs,
Oil Gas Production,
Oil Services,
pet food,
Pet Food,
pet products,
Pet products,
Pets Vets,
pets vets,
phamaceuticals,
Pharmaceuticals,
portfolio-strategy-asset-allocation,
Precious Metals,
Real Estate,
Real Estate Investment Trusts,
real-estate,
Regional - Northeast Banks,
reits,
short-ideas,
veterinary products,
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.



















View The Wall Street Transcript's Instablogs on:
Smart Phones, Smart Investments
The growth of the smart phone and tablet device market in the United States, at first powered by Apple's (AAPL) iPhone, is now becoming more competitive and driving significant valuation changes in both wireless carrier and wireless device stocks.
James D. Breen, of William Blair & Company, is a Wall Street Journal "Best on the Street" analyst. He sees the rise of the smart phone as a squeeze on wireless carrier profits. In this January 23rd interview from a report in the Wall Street Transcript, Mr. Breen states:
This wireless carrier cash squeeze in the United States could lead to more rapid valuation changes as bandwidth rich, cash poor companies become targets for larger rivals that have additional spectrum requirements.
Jonathan Chaplin of Credit Suisse (CS) is also considered a Best on The Street telecom analyst by The Wall Street Journal. In a recent interview Mr. Chaplin stated that Clearwire (CLWR) is going to become bandwidth bait as the spectrum squeeze plays out:
While the wireless carriers get squeezed for bandwidth, device manufacturers have also seen a big shake up in their sector. Kulbinder Garcha, a Managing Director at Credit Suisse with responsibility for global telecom equipment and IT hardware equity research, put it succinctly in this late January interview:
Mr. Garcha approves of investing in the current trends, with Apple being one of his favorite picks and Nokia (NOK) and Research in Motion (RIMM) falling further behind. Mr. Garcha is direct in his recommendations to investors: "Research In Motion has some real difficulties in terms of turning around their business…One of the things about Apple I think that's important to remember is that they only supply 230 carriers today, and globally Nokia and RIM supply 500 carriers. In other words, Apple is still building out their distribution."
Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.
Animal Companion Related Stock Picks
For investors pursuing a pure-play animal companion investment strategy, The Wall Street Transcript has identified pure-play pet-product companies such as PetSmart (PETM), VCA Antech (WOOF), IDEXX Laboratories (IDXX), MWI Veterinary Supply (MWIV) and Tractor Supply (TSCO) — and to a lesser degree the Patterson Companies (PDCO), Abaxis (ABAX) and the Omega Protein Company (OME).
Brian W. Nagel, a top ranked Managing Director and Senior Research Analyst at Oppenheimer & Co., has a positive take on PetSmart (PETM). He says PETM stock is recession resistant and the company has a strong management team:
To gain further exposure to a pure-play animal companion stock, Dawn R. Brock, a Senior Analyst with Kaufman Brothers, recommends IDEXX Laboratories (IDXX) for its direct sales to the global veterinary market. In a recent interview, she highlighted the investment attributes of IDEXX Laboratories:
Investors looking for stocks resistant in a recession or a slow-growth environment would do well to look further into companies offering animal companion goods and services.
Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.
Additional disclosure: Part 3 of a 3 part series titled:Pets & Vets: Investment Returns from our Animal Companions
Pets and Vets: Investment Returns from our Animal Companions: Part 2
Veterinary medical goods and services include pharmaceuticals intended for animal use. Many publicly traded large-cap pharmaceutical companies have significant divisions investing in this sector. Eli Lilly & Co (LLY) established its Elanco Pet division in 2007. The Elanco Pet subsidiary specializes in animal companion medicine distribution and development, and it has released two new products in the United States since 2007, one for flea control and the other for separation anxiety in dogs.
Similarly, Novartis (NVS) has its Novartis Animal Health division, Pfizer (PFE) has its Pfizer Animal Health division and Merck (MRK) its Merck Animal Health Division.
Pfizer currently has a dividend yield of nearly 4%, and the stock is at $21 per share, trading 26% above its 2011 low. The Animal Health division may perhaps provide a significant hedge against the continuing patent cliff concerns surrounding the company. However, even though the Animal Health division had $3.5 billion in sales last year and is on track for over $4 billion in sales in 2011, this is still less than 6% of over $70 billion in annual sales at Pfizer and will not replace revenues lost due to the Lipitor patent expiration.
At Merck (MRK), Q3 revenues at the animal health division were 20% higher than the previous year, with $826 million in sales, representing almost 7% of Merck’s Q311 revenues. Merck’s product offerings, particularly in companion animal vaccines, continue to attract investor interest, and the stock is at its 12 month high, at over $36 per share and currently yielding 4.7%.
But while these divisions’ sales and growth seem impressive, they are not large enough to warrant investing into the parent company. Additionally, the sector is facing turmoil as Morgan Stanley (MS) failed to pull off a merger of the animal health divisions of French pharmaceutical Sanofi Aventis (SNY) and Merck (MRK) earlier this year. The deal was called off because of antitrust concerns and creates a legal block to further consolidation in the sub sector.
Morgan Stanley (MS) is currently trading at slightly over $15 per share, off over 50% from 2011 highs.
Investors can look to other pure-play companies in the space, but many pet food companies are either privately held (Hartz Mountain, IAMs, Del Monte’s Meow Mix) or are a subsidiary of a much larger company, as is the case of industry giant Purina Pet Foods, now a division of Swiss food giant Nestle (NESN.VX).
The Pets & Vets report explores the investment thesis for these pure-play animal companion goods and services companies in Part 3 of Pets and Vets: Investment Returns from our Animal Companions.
Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.
Additional disclosure: Part 2 of 3 part series titled:Pets and Vets: Investment Returns from our Animal Companions